Previously, we have shown that the genetically modified human neural stem cells (NSCs) show remarkable migratory and tumortropic capability to track down brain tumor cells and deliver therapeutic agents with significant therapeutic benefit. Human NSCs that were retrovirally transduced with cytosine deaminase (CD) gene showed remarkable 'bystander killer effect' on the glioma cells after application of the prodrug, 5-fluorocytosine (5-FC). Interferon-b (IFN-b) is known for its antiproliferative effects in a variety of cancers. In our pilot clinical trial in glioma, the IFN-b gene has shown potent antitumor activity in patients with malignant glioma. In the present study, we sought to examine whether human NSCs genetically modified to express both CD and IFN-b genes intensified antitumor effect on experimental glioma. In vitro studies showed that CD/IFN-b-expressing NSCs exerted a remarkable bystander effect on human glioma cells after the application of 5-FC, as compared with parental NSCs and CD-expressing NSCs. In animal models with human glioma orthotopic xenograft, intravenously infused CD/IFN-b-expressing NSCs produced striking antitumor effect after administration of the prodrug 5-FC. Furthermore, the same gene therapy regimen prolonged survival periods significantly in the experimental animals. The results of the present study indicate that the multimodal NSC-based treatment strategy might have therapeutic potential against gliomas.
Introduction
Malignant glioma represents about 20% of all intracranial tumors. Despite advances in radiation therapy and chemotherapy administered after the surgical resection, the prognosis of malignant glioma remains poor with a median survival of o10 months. 1 The infiltrative nature of malignant gliomas and the limited penetration of chemotherapeutic agents through the tight blood-brain barrier are obstacles in the treatment of these formidable tumors.
Our group and others have previously shown that because of their remarkable migratory and tumor-tropic properties, neural stem cells (NSCs) represent a potentially powerful tool for the treatment of brain tumors by delivering therapeutic drugs into the intracranial glioma across the blood-brain barrier. [2] [3] [4] [5] Genetically modified NSCs selectively migrate toward brain tumor cells and deliver therapeutic agents with significant beneficial effects. In particular, NSCs that are retrovirally transduced with suicide genes such as the cytosine deaminase (CD) gene show a remarkable 'bystander killer effect' on 5-fluorocytosine (5-FC)-treated glioma cells. 3, [5] [6] [7] [8] Interferon-b (IFN-b) is known for its ability to interfere with viral replication and also for its antiproliferative effects on a variety of cancer cells. However, the efficacy of IFN-b is limited because of its extremely short half-life after intravenous administration as well as the systemic toxicity when this protein is administered at doses required to achieve the desired antitumor effect. In our pilot clinical trial, liposome-mediated IFN-b gene therapy has shown potent antitumor activity in patients with malignant glioma. 9, 10 The clinical trial suggested that the IFN-b gene delivery permitted locally sustained IFN-b production at levels sufficient to yield antitumor efficacy with minimal systemic adverse effects.
In the present study, we sought to examine whether intravenously administered human NSCs expressing CD and IFN-b migrate into the intracranial tumor bed through the blood vessels, and exhibit antitumor effect by the combined delivery of a suicide gene and a cytotoxic cytokine gene onto the experimental glioma.
Materials and methods

Human glioma cells and NSCs
A human glioma cell line, U251, was obtained from the American Tissue Culture Collection (ATCC, Manassas, VA) and grown in Eagle's minimal essential medium (Nissui, Tokyo, Japan) containing 10% fetal bovine serum, 5 mM of L-glutamine, 2 mM nonessential amino acids and antibiotics (100 U ml À1 of penicillin and 100 mg ml À1 of streptomycin) at 37 1C in a humidified atmosphere of 5% CO 2 . HB1.F3 (F3) human NSC line was generated from the human fetal telencephalon, and was immortalized by transfection with a retroviral vector encoding the v-myc oncogene, as described previously.
11 It has been confirmed that this human NSC line is capable of self renewal and is multipotent, that is, these NSCs can differentiate into cells of the neuronal and glial lineages, both in vivo and in vitro. 11 In this study, the clonal F3.CD.IFN-b line was derived from the parental F3.CD cells. 3 An expression plasmid was constructed using the pBabePuro retroviral vector (Cell Biolabs, San Diego, CA) as the backbone to include the human IFN-b cDNA transcribed from the long terminal repeat ends of the IFN-b gene. 9, 10 The IFN-b.puro plasmid and the MV12 envelope-coding plasmid (provided by Dr KS Aboody ) and gentamicin (20 mg ml
À1
). , and the culture was maintained for 3 more days. Each experiment was performed in triplicate. After the day 3, the cells were rinsed twice with PBS, and the adherent cells were detached using trypsin/EDTA. The number of viable cells was counted by the trypan blue method and expressed as the percentage of untreated U251 cells.
Dil labeling of NSCs
Clonogenic assay
The U251 cells were seeded in a 24-well plate (2 Â 10 4 cells per well) and cocultured with either F3.CD or F3.CD.IFN-b cells at various U251/F3 ratios ranging from 1:0 to 1:4. After 24 h culture, 5-FC was added to the medium at a final concentration of 500 mg ml À1 and the culture was maintained for 3 more days. The surviving cells were detached from the plates and re-seeded in a sixwell plate at a cell density of 500 cells per well (duplicate). The cells were cultured for 9 days and then stained with 0.25% 1,9-dimethylmethylene blue (Sigma-Aldrich) in 50% ethanol. The number of colonies was counted by two independent observers.
Intracerebral glioma model
The experiments were performed in accordance with the Guidelines for Animal Experiments of the Nagoya University Graduate School of Medicine. BALB/c female nude mice (SLC, Shizuoka, Japan) were anesthetized by administering an intraperitoneal (i.p.) injection of pentobarbital (60-70 mg per kg body weight). The animals were injected with 1 Â 10 6 U251 cells suspended in 5 ml of PBS using a Hamilton syringe under stereotactic guidance; the injections were administered into the forebrain (2 mm into the lateral side and 1 mm into the anterior side of the bregma; at a depth of 4 mm from the dural surface) for over 5 min. This intracerebral model was reproducible and exhibited a survival of B25-40 days.
Histological study of intravenously injected F3 cells into intracerebral glioma At 14 days after the establishment of the intracerebral glioma model, the animals (n ¼ 3) were injected intravenously through the tail vein with 2 Â 10 6 Dil-labeled F3, F3.CD or F3.CD.IFN-b cells diluted in 100 ml of PBS. The control animals (n ¼ 3) were injected with PBS alone. After 7 days, the animals were killed and transcardially perfused with 10% buffered formalin. Paraffin-embedded coronal sections were immunostained with rat antimouse-CD34 antibody (MEC 14.7; HyCult Biotechnology, Uden, Netherlands) followed by anti-rat Alexa Fluor 488 (Molecular Probes, Eugene, OR), and nuclei were counterstained with Hoechst 33342. CD34 has been most commonly used in studies of tumor angiogenesis, and the detection of CD34 in endothelial cells can be interpreted as indicative of angiogenesis. The adjacent sections also were processed for hematoxylin and eosin staining. 
Statistical analyses
The statistical significance of the observed difference was determined by analysis of variance (StatView software, SAS Institute, Cary, NC), and subsequently, Bonferroni's correction for multiple comparisons was applied. Survival curves were generated using the Kaplan-Meier method. The log-rank statistic (StatView) was used to compare the distribution of the survival times. All reported P-values were two-sided; a value o0.05 was considered to be statistically significant. 
F3 cells migrate to intracranial glioma in mice
The in vitro migration assay revealed that F3.CD.IFN-b cells had the same migratory pattern as that of the parental F3 cells (Figure 4) . Next, to ascertain the migratory capability of the NSCs from the vessels to the tumor mass, the Dil-labeled F3.CD.IFN-b cells were injected into the tail vein, and the newly formed tumor vessels were immunostained by using an anti-CD34 antibody. The Dil-labeled NSCs were found to be present 
F3.CD.IFN-b cells reduce tumor burden in experimental glioma in mice
We studied the growth inhibitory effect of genetically engineered NSCs (that is, F3.CD.IFN-b and F3.CD cells) on glioma cells in vivo. The mice with the U251-derived intracerebral tumor were injected with F3 cells, and the i.p. injections of 5-FC were administered for the next 10 days. The volume of the tumor was assessed on day 28 after FC treatment. As shown in Figure 6 , the residual tumor mass obtained in the group treated with F3.CD.IFN-b was much smaller than that obtained in the group treated with F3.CD cells (Po0.05).
F3.CD.IFN-b cells increase the survival periods in experimental animals
To determine whether F3.CD.IFN-b implantation followed by i.p. injections of 5-FC can produce therapeutic benefits in vivo, the implantation was performed 3 days after intracranial inoculation of U251 cells. We measured the survival periods of mice first inoculated with U251 intracranially, and subsequently with each type of NSCs (Figures 6 and 7) . Interferon-b is a type I IFN that exerts pleiotropic biological effects. 12 We have previously undertaken preclinical and experimental studies to investigate the application of cationic liposomes for delivering the IFN-b gene in glioma patients. In vitro experiments showed that the cationic liposome-mediated human IFN-b gene transfer into the cultured human glioma cells induced a cytocidal but not a cytostatic response even in In vivo experiments using mice implanted with human glioma cells revealed that local administration of cationic liposomes containing the human IFN-b gene induced an apparent reduction in the tumor growth and prolonged the survival. [13] [14] [15] [16] On the basis of these observations, a phase I clinical trial of IFN-b gene therapy was performed on five patients with recurrent malignant glioma. 9 At 10 weeks after treatment initiation, two patients showed more than 50% tumor reduction, whereas others did not show any significant improvement. The median survival was longer in the treated subjects than in the matched historical controls from our institution. After gene therapy, significant changes were observed in the histology and gene expression related to immune response, apoptosis and neovascularization. 17 A recent study has reported the findings of a phase I clinical trial, in which stereotactic injections of IFN-bexpressing adenoviral vectors were administered to 11 patients with malignant glioma and resulted in modest clinical outcome. 18 However, local administration of therapeutic IFN-b vectors used in these clinical trials could not address the issues of selective targeting of infiltrative satellite tumors.
To overcome this limitation, the inherently migratory, tumor-tropic NSCs can serve as a potentially powerful therapeutic tool. NSCs display remarkable tropism and migratory capacity to sites of malignant growth. 19, 20 In this study, we chose the human F3 NSC cell line, as it is a well-characterized and a well-established human NSC line. 3, [5] [6] [7] 11 No signs of local or systemic toxicity were observed in case of animals injected with F3 cells alone. Importantly, these cells can be modified to stably express a therapeutic transgene. In NSC-based gene therapy strategies targeting brain tumors, NSCs were mostly used to transport the CD/5-FC prodrug system to the tumor cells. [3] [4] [5] [6] [7] [8] Recently, Dickson et al. 21 showed that in mice, F3 human NSCs transiently expressing human IFN-b displayed tropism for sites of disseminated neuroblastoma, resulting in significant tumor growth. The sustained expression of IFN-b at disseminated sites of microscopic disease represents a novel therapeutic approach. In the present study, we investigated the additive efficacy of NSCs for delivering CD as well as IFN-b to the tumor site. Further studies are required to elucidate the mechanisms by which IFN-b intensifies the bystander effect of CD against glioma cells. Moreover, the application of NSCs in clinical settings raises some concerns. A recent study reported an NSC-derived brain tumor in a patient with ataxia telangiectasia who had been administered intracerebellar and intrathecal injections of human fetal NSCs. 22 In this study, we systematically delivered a human NSC cell line immortalized by v-myc. In our previous publication, we have reported that intravenously injected NSCs tend to be trapped in the spleen, kidney and liver. 23 Systemic administration of immortalized NSCs might cause neoplasm formation. These issues need to be addressed before clinical application. Nevertheless, our study indicates that the toxic effect against glioma cells exerted by a combination of two treatments is more effective than that exerted by CD-based suicide strategy. These findings support the possible application of a one-two-punch combination therapy for the treatment of malignant gliomas.
